Leading equine veterinary surgeon Ian Wright has been setting a legal precedent this week, as the Court of Appeal ruled that his ex-wife could not expect him to continue to fund her lifestyle and that she should earn her own living.
Ian, an RCVS Specialist in Equine Surgery and a partner at the Newmarket Equine Hospital, divorced his wife Tracey in 2008 after 11 years of marriage. As part of the settlement, Mrs Wright was given a £450,000 house and Mr Wright was ordered to pay £75,000 per annum, which included £33,200 spousal maintenance.
Last year, Mr Wright, 59, went to the High Court to ask for a reduction in maintenance, arguing that it was unfair to expect him to continue to fund his ex-wife indefinitely, even after he retired at 65, when she made no effort to find a job and support herself.
The case was heard by Judge Lynn Roberts, who agreed there was no reason why Mrs Wright had not worked in the six years since her divorce and said she had been: "evasive on the subject of her own earning capacity".
Mrs Wright challenged the decision in the Court of Appeal this week, where Lord Justice Pitchford rejected her fight to have her future maintenance reinstated, saying: "There is a general expectation that, once children are in year two, mothers can begin part time work and make a financial contribution" and: "The time had come to recognize that, at the time of his retirement, the husband should not be paying spousal maintenance".
Speaking to The Times, Mei-Ling McNab, a partner at Brachers law, said: "This landmark decision provides some much needed clarity and will be a game-changer for future big-ticket divorce cases. The ruling confirms that mothers with children aged over seven should have financial responsibility to support themselves."
Dr Thomason initially denied both heads of charge, but on the third day of the hearing he changed his plea and admitted the charge in its entirety.
The first part of the charge related to the fact that the seller of the horse was a both a client of Dr Thomason’s practice and a personal friend of his, and he therefore had a potential and/or actual conflict of interest.
Dr Thomason did not disclose this professional and personal relationship to the prospective purchaser before the pre-purchase exam.
The prospective purchaser only discovered Dr Thomason’s relationship with the seller when reading the vetting certificate at home, and stated that, in the past, she had had a similar experience in which the horse was then found to be lame. She later found out the extent of the personal relationship, when invited to join the seller on a social media site.
The Committee found that, in this set of circumstances, Dr Thomason should not have undertaken the pre-purchase exam at all, and, at the very least, disclosed his personal and professional relationship with the vendor.
The Committee also found that although Dr Thomason did have a system in place to inform any prospective purchasers if the vendor was a client of his practice, this failed to work on this occasion and neither the practice nor Dr Thomason told the prospective buyer that the seller was a client before booking the pre-purchase exam. Dr Thomason had no similar system in place to disclose any close friendships with sellers.
Dr Thomason did not consider there was a conflict of interest as he felt confident he could carry out the pre-purchase exam impartially. In addition, it was his belief that the seller had been alerted to the conflict through a system in place at his practice, implemented to safeguard against this type of error. He stated that he in no way attempted to hide his relationship with the seller to the prospective purchaser.
It was not alleged that Dr Thomason had acted dishonestly.
Ultimately, the Committee found Dr Thomason not guilty of disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "Whilst the Committee concluded that the respondent’s view of his obligations to disclose both the professional and personal relationships he had with the vendor was mistaken, it did not find any improper motivation on his part. It has already noted that he sought to disclose to the prospective purchaser through his system the fact that the vendor was a professional client of his.
"The Committee has weighed all these matters very carefully. It is for the client to determine whether or not to proceed with a PPE when in possession of all relevant facts in relation to any potential conflict of interest, and not for the veterinary surgeon to decide. The autonomy of the client must be respected. The Committee was firmly of the opinion that a failure to comply with the Code is very serious. However, taking into account the particulars of this case, the Committee does not consider that the actions of the respondent amount to disgraceful conduct in a professional respect."
The BEVA has welcomed the news, whilst expressing its concern that the drug was suspended without consultation with the veterinary profession in the first place.
Jon Pycock, BEVA President said: "It remains a concern to BEVA that this mechanism was not put in place before the suspension of flunixin was imposed. Contrary to assertions by the VMD, wholesalers were unable to meet the demands of the veterinary profession and clinical use of this medicine was disrupted within 24 hours of the VMD’s initial announcement.
"We are surprised by the Regulator’s lack of awareness of availability in the supply chain and question why there was no consultation with the veterinary sector before the suspension was enacted. The VMD has been aware of this issue since March 2018 and it appears that no contingency was put in place to consider the animal welfare impact of this decision until it was too late."
BEVA Junior Vice President and Specialist in Equine Surgery Tim Mair continued: "Flunixin is a unique medicine in managing pain and sepsis in horses with colic. The VMD appeared to believe that this medicine could be substituted for other veterinary medicines and this is simply not the case. The release of stock from manufacturers is a short-term solution and, looking forward, we would like assurances that the VMD will fast track applications for the modification of product licenses to ensure that equine vets have continued access to these products."
Professor Kate White, Senior Vice President of the Association of Veterinary Anaesthetists added: "Provision of pain relief is essential to maintain animal welfare. The loss of these products would hinder the work of vets working with horses and donkeys and in zoos where they are first line drugs for the management of pain. Use of flunixin in these animals can be undertaken safely with no impact on human health."
Stock of flunixin held by manufacturers will be distributed alongside a ‘caution in use’ letter that will explain the restricted use of this product. BEVA is reminding all equine vets that the horse’s food chain status must be checked when using this product – either using the paper passport or the recently launched chip checker on the central equine database website.
Anesketin solution for injection, containing Ketamine 100 mg/ml, is indicated for induction of anaesthesia. It can also be used as a sole agent for restraint and minor surgical procedures where muscle relaxation is not required in cats.
Anesketin was previously available in 10ml or 50ml bottles. Dechra says it has added the new 5ml vial in response to feedback from veterinary practices.
Dechra Brand Manager Craig Sankey said: "Anesketin is one of our most popular products in our range due to its versatility. It can be used in combination with appropriate sedatives and analgesics in cats, dogs and horses for induction of anaesthesia.
"5ml Anesketin will help practices comply with controlled drug legislation, saving time and effort in denaturing out of date stock and reducing wastage."
He added: "The introduction of the smaller bottle demonstrates our commitment to responding to the requirements of veterinary professionals and providing a range of high quality products that provide the most effective solution within day-to-day practice."
Support tools are available for customers to order online at www.dechra.co.uk, including an Anesketin controlled drug register.
Nerfasin vet is available in two concentrations - a 100 mg/ml (10%) solution for cattle and horses and 20 mg/ml (2%) solution for cattle, horses, cats and dogs.
Nerfasin vet is on sale in 25 ml vials.
For more information visit: www.dechra.co.uk.
Neil, a Senior Lecturer at the University of Edinburgh Royal Dick School of Veterinary Studies, is an equine veterinary surgeon who has worked in large and small animal practice in the UK and Australia. Neil is clearly multi-talented: on top of his many and various career achievements, he was in the Cambridge Footlights and has performed in four Edinburgh Fringe Festival shows. He also plays the piano.
Danny is another multi-talented veterinary surgeon, currently working as an equine locum and well-known in the profession as an RCVS Council Member, the founder of Veterinary Voices and a campaigner against irrational forms of veterinary medicine such as homeopathy.
Ian Fleming is a Senior Vet at the PDSA, standing as an independent candidate for the Halesowen and Rowley Regis constituency.
If I was a betting man, my money would have to be on Neil: Penrith and the Border has been held by the Conservatives since 1950, most recently by Rory Stewart. Danny, on the other hand, needs to overturn a 7200 Conservative majority in his constituency, something which the latest polls suggest is a bit of an outside bet. Still, stranger things have happened.
The first charge was that in April 2016, having examined a horse named Alfie on behalf of his owner, Mr Villar gave an opinion to the potential buyers but failed to make it clear that he had not undertaken a pre-purchase examination; failed to declare to the buyer that he had a conflict of interest with regard to the owner; and, failed to explain the pre-purchase examination process to the buyers.
The second charge was that, in July 2016, during a telephone conversation with the buyer, Mr Villar was dishonest and failed to provide clear and accurate information because he told the buyers that he had only been asked to trot Alfie to check he was sound when he had, in fact, carried out a more substantial examination.
The third charge was that Mr Villar had offered to either the owner or the buyer, or both, that he would prepare a veterinary insurance certificate in relation to Alfie when he knew he did not have sufficient records (eg the microchip or passport number) to do so.
The fourth charge was that Mr Villar failed to respond adequately to communications from the buyers about Alfie.
The Committee found that Mr Villar had not in fact carried out a pre purchase examination (“PPE”) and referred to guidance from the British Equine Veterinary Association which identified that pre-purchase examinations are carried out on behalf of buyers. It noted that in this case, Mr Villar had undertaken an examination on behalf of the owner. Accordingly, it did not find that Mr Villar had failed to explain the PPE process to the potential buyers.
However, the Committee did find that Mr Villar had failed to declare that he had a conflict of interest in regards to Alfie’s owner. The Committee said that Mr Villar should have told the buyer that he had been acting on behalf of the owner and was not a neutral party in the potential sale.
The Committee found all aspects of the second charge not proven, on the basis that it was not satisfied so as to be sure that Mr Villar had told the potential buyers that he had only been asked to trot Alfie and check that he was sound.
The Committee found all aspects of the third charge proven on the basis that, in an email sent to the College in March 2016, Mr Villar admitted that he did not have the sufficient records to prepare a veterinary insurance certificate.
The Committee found the fourth charge not proven on the basis that the buyers were not his clients. The Committee therefore concluded that he had no obligation to respond to them, and indeed could not do so in certain respects in order to preserve the confidentiality of his client.
The Committee then determined that the charges found proven, when taken individually or in combination, did not amount to serious professional misconduct.
Ian Green, chairing the Committee and speaking on its behalf, said: "The following mitigating factors were present in this case: the circumstances of the incident, the fact that there was no premeditation, the fact that he was requested by his client to advance an opinion to [the buyers] concerning Alfie and that his ill judgement was on the spur of the moment and the fact that he had no financial gain. These are all important factors. Likewise, the fact that he did not know that the [buyers] regarded him as their pre-purchase examination vet is an important matter.
"The respondent’s conduct was clearly against the principles of behaviour articulated by Mr Morley [who acted as an expert witness for the College] in his expert report and in his evidence. Nevertheless, the Committee does not find that in the particular circumstances of this case, namely being asked to speak to a potential purchaser without warning and without being made aware of the contractual arrangements which had been made between the respondent and [the owner], the respondent should not properly be the subject of a finding of disgraceful conduct in a professional respect."
Fynadyne had been removed from sale last year after the Veterinary Medicines Directorate suspended the sale of any medicinal products containing the excipient diethanolamine (DEA), following advice to the European Medicines Agency that it could pose a risk to human health.
Finadyne 50mg/ml Solution for Injection is indicated for the alleviation of acute inflammation and pain in both cattle and pigs. It is also indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses.
The reformulated product has a shelf life of three years and is now available from wholesalers in 50ml and 100ml vials.
For further information, contact your MSD Animal Health account manager.
Zoetis, maker of Zylexis, is highlighting a new review published in Veterinary Immunology and Immunopathology, which has concluded that immune-modulators may provide a valuable contribution to the reduction of some equine respiratory diseases
The study reviewed the immune-modulators Parapoxvirus ovis and Propionbacterium acnes for the prevention of respiratory disease and other infections in the horse.
Parapoxvirus ovis (iPPVO) and Propionibacterium acnes (P.acnes) are currently used in equine medicine as immune-modulators for prophylactic treatment or adjunct to conventional therapy in order to improve immune defences, to prevent or treat infectious diseases. Their mode of action relies on a non-antigen-specific interaction with the innate and/or adaptive immune responses. iPPVO stimulates and regulates cytokine secretion by a number of leucocytes, while P. acnes acts primarily through activation of macrophages.
The review, conducted by Romain Paillot of the Animal Health Trust, Centre for Preventive Medicine, Newmarket, examined current scientific literature and reports on the use of immune-modulators in horses, particularly for the prevention or treatment of equine respiratory disease.
Stress factors such as weaning, transport and co-mingling predispose horses to infection and increase susceptibility to respiratory pathogens such as Streptococcus zoopidemicus and EHV-1/4. In the past 15 years iPPVO has been tested against several equine infectious respiratory diseases.
The review examined the results of studies on the beneficial use of iPPVO to limit the severity of respiratory infectious diseases in young horses, one of which evaluated the use of iPPVO for protection in yearlings exposed by contact challenge to EHV-1 or EHV-42,3,4. Yearlings treated with iPPVO were co-mingled with horses experimentally infected with EHV-1 and the trial was repeated with horses infected with EHV-4. Horses treated with iPPVO showed a 40% reduction in disease severity in the EHV-1 study and a 61% reduction in the EHV-4 study.
Further studies showed significantly increased frequency of recovery in horses with clinical signs of respiratory disease that had been treated with P. acnes. The decrease in disease severity was also significantly improved in the treated groups5,6.
Romain Palliot concluded: "Non-specific immune-modulators such as iPPVO or P. acnes may not provide protection against direct infection or transmission of respiratory pathogens but they seem to contribute to the reduction of the disease severity, subsequently reducing the frequency of complications and improving the rate of recovery."
References
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager, said: "Arti-Cell Forte is the first 'ready-to-use' stem cell-based product to be licensed in any veterinary species, and the only stem cell treatment to contain induced cells, representing a significant leap forward in both stem cell therapies and medicine as a whole.
"Arti-Cell Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage. Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses¹."
"This makes Arti-Cell Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease."
Arti-Cell Forte is available direct from Boehringer Ingelheim to veterinary practitioners.
It needs to be stored at ultra-low temperatures to maintain its two year shelf life from manufacture, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately prior to injecting.
The company is providing full training on storage and administration via face-to-face CPD at practice meetings or specific CPD events*.
For more information, contact your local territory manager or ring Boehringer's Technical Services Team on 01344 746957, or email vetenquiries@boehringer-ingelheim.com
Reference
A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
Ms Gatehouse faced two charges, the first being that she inaccurately assured another veterinary surgeon that she had vaccinated a horse against influenza and tetanus when she had not, and she subsequently failed to undertake adequate checks to confirm whether she had done so.
The second charge was that she later made a false entry in the same horse’s clinical records to cover up her previous inaccurate statement.
Ms Gatehouse admitted the facts alleged in relation to both charges and also admitted that in relation to the second charge she was guilty of disgraceful conduct in a professional respect.
The Committee, having heard submissions from Counsel for the RCVS and Ms Gatehouse found her guilty of disgraceful conduct in relation to the first charge.
Under the first charge the Committee found that she had breached the RCVS Code of Professional Conduct for Veterinary Surgeons by not keeping clear, accurate and detailed clinical and client records, and by acting in a manner that was likely to undermine public trust in the profession.
They also considered that her falsehood was unpremeditated, and that the decision was made in a moment of panic. Ultimately, however, by claiming the horse was vaccinated to another veterinary surgeon and not taking the necessary steps to confirm this, she failed to put the welfare of the animal first, potentially endangering it and any other horses it came into contact with, as well as potentially jeopardising the position of the veterinary surgeon she confirmed it to.
Having found Ms Gatehouse guilty of serious professional misconduct in relation to both parts of the charge the Committee then considered its sanction against her. In mitigation the Committee considered the fact that she had been in practice for 22 years without any untoward conduct, the testimony of three witnesses who attested to her being an honest and trustworthy practitioner, and the fact that Ms Gatehouse was in a troublesome relationship with the complainant until June 2014 which led her to be reluctant to contact him to correct her initial confirmation.
In summing up Stuart Drummond, Chair of the Committee, said: "The Committee has considers that it is material to have regard to the general emotional state to which the Respondent was reduced by the controlling and debilitating conduct of her then partner when they were living together and the consequential loss of self-esteem and ability to stand up to him and his demands. The deleterious effect of an abusive relationship lingers after such a relationship ends.
"Taking into account this knowledge, the Committee considers that the period of suspension that would, in other circumstances, be entirely merited, can properly be reduced in this instance to reflect the fact that this veterinary surgeon would not have acted as she did during this period but for the fact that her judgement was adversely affected by her experience at the hands of her then former partner.
"The decision is that, whilst it is necessary, in order sufficiently to protect animals and the wider public interest, to impose a period of suspension from practice, that period can be reduced to one of two months. In so concluding the Committee wishes to make it clear that this decision reflects the special features of this case."
Ms Gatehouse can choose to appeal the decision after a period of 28 days.
Dr Crawford sent the email to his client, Mrs X, on 15 July 2014, the day on which Mrs X’s horse was due for insemination using horse semen supplied from a horse in Germany. However, the semen had arrived without the Intra Trade Certificate, a requirement for intra-EU inseminations, and so Dr Crawford proceeded to contact the Department for the Environment, Food and Rural Affairs (Defra) for alternative authorisation.
Just after 4:30pm on that day, Mrs X received a text from Dr Crawford advising her that he had received authorisation from the AHVLA, and would forward to Mrs X the AHVLA authorisation email. It later transpired that that the email had in fact been fabricated by Dr Crawford using an email that he had previously received from the AHVLA regarding another matter.
Dr Crawford faced the following charges:
Fabricating an e-mail purporting to be from the veterinary officer at the AVHLA, authorising use of semen from a horse for insemination, when in fact he had not received such authorisation.
Dishonesty in relation to the e-mail described above.
His conduct gave rise to spread of infectious disease which had the potential to affect equine animal health and welfare in the region.
Dr Crawford admitted the first two charges, but denied that his actions had given rise to the risk of disease.
The Committee found the first two charges proved, and moved on to determine the facts of the third charge. They took into account that Dr Crawford had received verbal confirmation that the semen was safe, and that the health papers had been stamped accordingly. He had not, however, seen a copy of this certificate and so there was no guarantee that the semen was safe to use at the time he sent the fabricated email. On consideration of the facts, the Committee found this charge proved, as Mrs X’s mare could have been infected and subsequently could have adversely affected equine animal health and welfare in the region.
They also found that his entire course of action had fallen far short of what is expected of a veterinary surgeon, and that it amounted to disgraceful conduct in a professional respect.
When determining sanction, the Committee took into account a number of aggravating factors, namely the risk of injury to animals, an element of pre-meditation, a disregard for the role of the AHVLA, impersonating a fellow veterinary surgeon, and intending to deceive a veterinary surgeon as well as a member of the public.
It did also, however, take into account the mitigating factors – that there was no injury to the animal, and that it was a single isolated incident from which Dr Crawford did not stand to make any financial gain.
The Committee therefore decided to order the Registrar to suspend Dr Crawford’s registration for 12 months.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee did consider whether to remove Dr Crawford from the Register. However, in light of the significant mitigation in this case, the fact that this was an isolated incident in an otherwise unblemished career, together with his acceptance from the outset that he had been dishonest and his assurance that he would never behave in this way again, the Committee decided that in all the circumstances to remove him from the Register would be disproportionate."
Dr Crawford can lodge an appeal with the Privy Council within 28 days of being notified of the Disciplinary Committee's decision.
The company says the new product has been launched in response to demand from UK equine veterinary surgeons specialising in dentistry
Hexarinse for Horses is presented as a palatable, mint-flavoured, ready-to-use formulation in a five litre container.
Virbac says the antibacterial action of chlorhexidine supports the maintenance of oral health after dental procedures and may aid the management of periodontal disease, oral inflammation and the management of peripheral caries.
For further information, speak to your local Virbac territory manager or contact Virbac Limited on: 01359 243243 or enquiries@virbac.co.uk.
Dexafast is an injectable corticosteroid with potent, medium-acting, anti-inflammatory activity, indicated for the treatment of a range of inflammatory and allergic conditions in both small and large animal clinical practice.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said: "Dexafast 2mg/ml is an excellent addition to our range. This formulation of dexamethasone is used across many species on a daily basis, and Dexafast 2mg/ml gives vets a high-quality presentation of a staple medicine."
Dexafast is available in a 50ml bottle.
For further information, contact your local Forte Territory Manager, visit: https://www.fortehealthcare.ie/product/dexafast-uk-only, or email: enquiries@fortehealthcare.com.
Kruuse has announced that it has become the exclusive UK and Ireland distributor for Pulse Veterinary Technologies LLC shockwave systems, including the Versatron, Versatron 4paws and Equitron.
Shockwave therapy, otherwise known as extracorporeal shock wave therapy (ESWT), uses a high-energy sound wave that rapidly increases pressure as it travels through tissue. It is a non-invasive modality used to stimulate healing particularly in ligament, tendon or boney structures.
Andrew Groom, Managing Director, Kruuse UK Ltd said: "This agreement widens the Kruuse equine and small animal capital equipment profile within the UK and Ireland; increasing the range of technologies available to the veterinary practitioner , whilst providing aftercare support of existing shockwave users".
Eric Goorno , Chief Executive Officer, Pulse Veterinary Technologies LLC said: "This exciting partnership will further enhance our presence within the veterinary industry and allow Kruuse UK to bring leading edge technology to its customers, building upon its strong relationships within veterinary practices".
ECM, a French manufacturer of ultrasound devices, has launched Exago, a new mobile veterinary ultrasound device which the company says is particularly suited for use with horses and pets.
ECM says the main features of the new device are:
For more information, visit: http://www.agroscan.com/
The new briefing will summarise the latest veterinary innovations, resources and research which are of practical value to vets in practice. In other words, only what you strictly need to know.
Need to Know content will be curated by three practising veterinary surgeons: Liz Barton MRCVS (Small Animal, pictured right), Aoife Byrne MRCVS (Equine), and Rachel Tennant MRCVS (Farm Animal). It replaces InDigestion, VetSurgeon.org’s previous monthly newsletter which only linked to the most popular content on the site itself. By contrast, Need to Know summarises developments from all sources.
VetSurgeon.org Editor Arlo Guthrie said: "In these days of information overload, our aim here is to provide busy veterinary surgeons with a really succinct summary of anything that really matters, wherever it comes from."
Need to Know is the result of a new partnership between VetSurgeon.org and Vetsnet, a veterinary wellbeing resource hub set up by Liz to support her colleagues in the profession, and the bulk of any additional advertising revenue generated by the initiative will be ploughed back into Vetsnet.
Arlo added: "Since VetSurgeon launched back in 2008, content has been entirely curated by me. I like to think that has worked reasonably well. Still, having practising veterinary surgeons involved editorially is a big step forward in making sure our content is always useful and relevant."
Anyone subscribed to receive emails from VetSurgeon.org on registration will automatically receive Need To Know.
If you have subscribed, but are NOT receiving emails from VetSurgeon.org, you usually need to log into your email account online and move emails from VetSurgeon.org from your spam or junk folder into your inbox. Some email providers (notably Hotmail) also allow you to ‘whitelist’ emails from certain people and organisations. In that case, add 'vetsurgeon.org' to your whitelist.
If you have unsubscribed from emails from vetsurgeon.org in the past and now want to resubscribe, email support@vetsurgeon.org and we’ll remove you from the exclusion list.
The range includes:
Fluodrop (the first fluorescein product specifically designed for veterinary use)
Ocryl - an ocular and periocular cleanser that can also be used to reduce and prevent unsightly tear staining
Ocular lubricants (carbomer and hyaluronic acid based)
Clerapliq – a novel molecule to the UK veterinary market that is used to help restore and regenerate the corneal extracellular matrix
The products will be supported with a selection of materials to help vets, nurses and pet owners in the maintenance of corneal health, including diagnosis and treatment guidelines, anatomical guides, posters and client educational and treatment aids to help with compliance.
William Peel MRCVS, product manager at TVM-UK said: "Our Corneal Focus Range is an exciting way to expand on our product portfolio following the successful introduction of our ‘Anti-tox’ range.
"With ‘Anti-tox’ we successfully managed to make vets and nurses lives easier by providing education and materials alongside a great range of products to help when dealing with poisoning cases in practice. We also attempted to make clients more aware of the dangers of poisoning in pets.
"We hope to emulate this approach and success with our Corneal Focus Range – by developing a wealth of materials for vets, nurses and clients to aid them in managing and understanding ophthalmology cases – and by providing quality products."
TVM UK will be showcasing its new products and support services at the London Vet Show (stand P40) this November.
For more information, visit: http://www.tvm-uk.com/
Zoetis has announced the launch of Ketavet.
The intravenous anaesthetic solution containing ketamine is available in 10ml and 50ml presentations. The new product coincides with the re-classification of ketamine as a schedule 2 drug.
Ketavet is a clear, colourless solution for injection containing ketamine 100 mg/ml (equivalent to 115.36 mg/ml ketamine hydrochloride) with benzethonium chloride 0.1 mg/ml as a preservative. It can be used to induce anaesthesia in horses in conjunction with xylazine, detomidine or romifidine.
Ketavet, along with other ketamine containing products, has been moved to Schedule 2 of the Misuse of Drugs Regulations, which took effect from 30 November 2015. This enables tighter controls on the record keeping, prescribing and safe custody of products containing this active. More information on the specific requirements which will need to be met following the schedule change can be found on the VMD website https://www.gov.uk/government/news/amendments-to-the-misuse-of-drugs-regulations-2001
Penny McCann, Equine Product Manager at Zoetis said: "Ketavet is an important product in our anaesthesia portfolio. We are keen to help veterinary surgeons keep up-to-date with the reclassification of ketamine and with this in mind our new product packaging clearly reflects ketamine’s revised status as a schedule 2 drug."
For more information, contact your Zoetis Account Manager.
Dechra Veterinary Products has launched TAF Spray (thiamphenicol), a next generation antibiotic wound spray for superficial wound infections in horses, cattle, goats, sheep and pigs.
Dechra says TAF Spray can also be used to treat infections of the claw and hoof in cattle, goats and sheep such as foot rot, interdigital dermatitis and digital dermatitis.
TAF Spray is the only licensed wound spray for horses and has a zero day meat withdrawal period for horses, cattle, goats, sheep, and 14 days for pigs.
Dechra is also highlighting the fact that TAF Spray is the only golden yellow coloured product of its kind on the market, allowing treatment areas to be distinguished clearly.
Brand Manager Emma Jennings said: “Dechra has developed TAF Spray in direct response to the research we conducted among farmers".
The research1 showed that 51% of the veterinary surgeons had used an antibiotic spray for the treatment of digital dermatitis – an infection that 92% of farmers had experienced in their livestock in the past 12 months.
Emma added: "Thiamphenicol is a highly effective antibiotic. With the brightly coloured spray format making it distinguishable from other treatments and a can that is able to be used in upright and inverted positions, we are sure that TAF Spray will become a popular product among veterinary professionals.”
TAF Spray comes in a 150ml can with a 360-degree nozzle which allows wounds to be targeted at any angle.
For further information about Dechra’s antibiotic portfolio, visit www.dechra.co.uk
Kruuse is to launch a new Manuka honey dressing at BEVA 2011 in September.
Kruuse says that honey has been used as a topical anti-microbial agent and dressing for over 2000 years, and that honey derived from the nectar of the Manuka tree (Leptospermum scoparium) has its own unique chemical properties. Manuka honey contains glucose oxidase imparted by the bees during its collection and storage. This enzyme facilitates low level release of hydrogen peroxide when in the presence of wound exudates and thus supports cellular proliferation and metabolism through an antioxidant effect. The high sugar and low pH content creates a high osmotic potential which gives honey excellent debridement and anti-inflammatory properties.
The company says that one of the biggest difficulties with the use of honey in wound dressings is ensuring that once applied it stays over the wound area. Many attempts to coat dressings have been unsuccessful; often the active honey ingredient is left within the packaging severely reducing the effectiveness of the dressing. Kruuse says its Manuka dressings have the active honey impregnated 'within' the dressing, which ensures precise and easy application even if wearing surgical gloves.
The Kruuse Manuka dressings range comes in impregnated adherent (Kruuse Manuka AD), non-adherent dressing (Kruuse Manuka ND) and 15g tube of Manuka G. Each dressing comes in 3 sizes 5x5 cm , 10x12.5 cm and the KRUUSE Manuka roll (10x100 cm) a unique product ideal for large vertical wounds. E.G. Equine forelimb.
Kruuse also says that the antimicrobial potency in Manuka honey is rated by a standardised rating known as Unique Manuka Factor (UMF). The higher the UMF the better the antimicrobial effect. A minimum UMF of 10 is required to ensure sufficient effect in the wound environment, Kruuse Manuka Honey Wound Dressings have a Unique Manuka Factor of 15.
There is a restricted annual supply of Manuka honey as this unique product supply is controlled by a small number of producers in New Zealand. Many current honey products available use blends of Manuka honey with other poorer quality honey, these are often less effective. Kruuse Manuka uses 100% Manuka honey in all its dressings with the profits of the sale being returned directly to the Maori tribe that oversee the production of Manuka honey.
Andrew Groom, Managing Director Kruuse UK Ltd. said: "I am very excited that we have been able to secure a direct connection to supply this unique product with the knowledge that the Maori suppliers will see the returns for generations to come whilst this new range of dressing will add huge versatility for day to day wound management!"
Renutend contains primed mesenchymal stem cells (MSCs) which Boehringer says are specifically targeted to reduce scar tissue formation so horses can return to the intended level of performance, with a reduced risk of re-injury1.
According to the company, a single dose decreases scar tissue formation with consistent and proven results 2.
RenuTend is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell Forte, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
RenuTend will be available in September this year.
In the meantime, Boehringer is encouraging veterinary surgeons to register their interest with their BIAH representative or call 01344746960 in order to get updates or product information as soon as it becomes available.
Metacam 40 mg/ml solution for injection for cattle and horses contains 40 mg/ml of meloxicam, and is available in either 50 ml or 100 ml presentations. It is approved for subcutaneous or intravenous use in cattle, and intravenous use in horses.
Boehringer says the introduction comes on the back of a recent large-scale landmark study that found adding Metacam to standard antibiotic therapy for mastitis resulted in a greater first-service conception rate, fewer inseminations required to conceive and a higher probability of pregnancy by 120 days post-calving when compared to cows receiving antibiotic therapy alone1.
Boehringer Ingelheim’s technical manager Kath Aplin said: "By reducing the pain and inflammation caused by mastitis and other conditions, the use of Metacam 40 can result in improvements in cattle health and welfare, and may help limit any reduction in feed intakes. This is central to efficient herd management and productivity."
The company adds that new Metacam 40 mg/ml formulation offers a lower volume dose compared to the existing 20 mg/ml presentation, giving vets more flexibility in their use of Metacam.